Viridian Therapeutics Q2 2026 net loss widens to $127.1 million as Lumvoa launches
Viridian Therapeutics reported second quarter 2026 results, its first full quarter after the June 26, 2026 FDA approval of Lumvoa for thyroid eye disease. Total revenues were $284 thousand, up from $75 thousand a year earlier, but the net loss widened to $127.1 million from $100.7 million, and selling, general and administrative expenses rose to $55.0 million from $20.2 million to build out commercial infrastructure.
Key points
- Net loss was $127.1 million, or $1.05 per share, versus $100.7 million, or $1.00 per share, in the second quarter of 2025.
- Total revenues were $284 thousand versus $75 thousand a year earlier.
- Selling, general and administrative expenses were $55.0 million versus $20.2 million; research and development expenses fell to $71.6 million from $86.6 million.
- Cash, cash equivalents and marketable securities were $981.5 million as of June 30, 2026, after convertible debt and equity financing in May 2026 with gross proceeds of $394 million.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.